Skip to main content

Repligen Corporation (RGEN) Stock Analysis

SellModerate Confidence

Healthcare · Medical Instruments & Supplies

Earnings in 5 days (2026-05-05). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Momentum 2.7/10 is below the 5.0 floor at $115.28 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: XCell ATF® systems suppliers; Earnings in 5 days (event risk).

Repligen develops and commercializes bioprocessing technologies for biological drug manufacturing across four franchises: Filtration, Chromatography, Process Analytics, and Proteins. It sells consumables and hardware primarily to global biopharmaceutical companies, CDMOs, and... Read more

$115.28+40.4% A.UpsideScore 5.4/10#10 of 25 Medical Instruments & Supplies
Stop $107.21Target $161.80(analyst − 10%)A.R:R 3.5:1
Analyst target$179.78+55.9%18 analysts
$161.80our TP
$115.28price
$179.78mean
$220

Sell if holding. Momentum 2.7/10 is below the 5.0 floor at $115.28 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: XCell ATF® systems suppliers; Earnings in 5 days (event risk). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.4/10, moderate confidence.

Passes 5/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 5d<=7d. Suitability: moderate.

Thesis

Rewards
Strong earnings beat streak (3/4)
Strong growth profile
Analyst upside: 40%
Risks
Concentration risk — Supplier: XCell ATF® systems suppliers
Earnings in 5 days (event risk)
Negative momentum

Key Metrics

P/E (TTM)131.5
P/E (Fwd)44.9
Mkt Cap$6.4B
EV/EBITDA50.6
Profit Mgn6.6%
ROE2.4%
Rev Growth18.1%
Beta1.19
DividendNone
Rating analysts28

Quality Signals

Piotroski F9/9

Options Flow

P/C4.87bearish
IV79%elevated
Max Pain$250+116.9% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHSupplierXCell ATF® systems suppliers
    10-K Item 1A: 'only a small number of suppliers are currently qualified to supply materials for the XCell ATF® systems'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Ma Position
1.5
Volume
1.9
Rsi
4.5
Obv
5.7
Below 200-MA, MA slope flat

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Value Rank
0.6
Quality Rank
4.4
Growth Rank
8.2
Industry growth leader
GatesMomentum 2.7<4.5Death cross (50MA < 200MA)EARNINGS PROXIMITY 5d<=7dA.R:R 3.5 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARSuitability: Moderate
RSI
45 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $109.50Resistance $141.46

Price Targets

$107
$162
A.Upside+40.4%
A.R:R3.5:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Momentum score 2.7/10 — below 4.5 minimum
! Death cross — 50-day MA below 200-day MA
! EARNINGS_PROXIMITY:5d<=7d

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-05-05 (5d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is RGEN stock a buy right now?

Sell if holding. Momentum 2.7/10 is below the 5.0 floor at $115.28 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: XCell ATF® systems suppliers; Earnings in 5 days (event risk). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $107.21. Score 5.4/10, moderate confidence.

What is the RGEN stock price target?

Take-profit target: $161.80 (+40.4% upside). Prior stop was $107.21. Stop-loss: $107.21.

What are the risks of investing in RGEN?

Concentration risk — Supplier: XCell ATF® systems suppliers; Earnings in 5 days (event risk); Negative momentum.

Is RGEN overvalued or undervalued?

Repligen Corporation trades at a P/E of 131.5 (forward 44.9). TrendMatrix value score: 5.2/10. Verdict: Sell.

What do analysts say about RGEN?

28 analysts cover RGEN with a consensus score of 4.1/5. Average price target: $180.

What does Repligen Corporation do?Repligen develops and commercializes bioprocessing technologies for biological drug manufacturing across four...

Repligen develops and commercializes bioprocessing technologies for biological drug manufacturing across four franchises: Filtration, Chromatography, Process Analytics, and Proteins. It sells consumables and hardware primarily to global biopharmaceutical companies, CDMOs, and integrators worldwide. 39.5% of 2025 revenues were denominated in foreign currencies.

Related stocks: WST (West Pharmaceutical Services, I) · MMSI (Merit Medical Systems, Inc.) · STVN (Stevanato Group S.p.A.) · RMD (ResMed Inc.) · ATRC (AtriCure, Inc.)